Castle Biosciences (CSTL) CEO details RSU grants, conversions and tax share disposals
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.
The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.
Positive
- None.
Negative
- None.
Insider Trade Summary
59,097 shares exercised/converted
Mixed
15 txns
Insider
MAETZOLD DEREK J
Role
Pres. & Chief Exec. Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 31,110 | $0.00 | -- |
| Exercise | Restricted Stock Units | 27,987 | $0.00 | -- |
| Exercise | Common Stock | 59,097 | $0.00 | -- |
| Tax Withholding | Common Stock | 17,931 | $28.17 | $505K |
| Grant/Award | Restricted Stock Units | 102,597 | $0.00 | -- |
| Tax Withholding | Common Stock | 19,043 | $27.57 | $525K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 62,218 shares (Direct);
Common Stock — 123,752 shares (Direct);
Common Stock — 52,923 shares (Indirect, By The Maetzold Descendants 2020 Trust)
Footnotes (1)
- Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. The RSU's vest in four equal annual installments beginning on March 03, 2027. On March 4, 2024, the Reporting Person was granted 124,437 RSUs which vest in four equal installments beginning on March 4, 2025. On March 4, 2025, the Reporting Person was granted 111,948 RSUs which vest in four equal installments beginning on March 4, 2026.
FAQ
What insider stock transactions did CSTL CEO Derek Maetzold report on this Form 4?
Derek Maetzold reported RSU grants, RSU conversions, and tax-related share dispositions. He received 102,597 RSUs, had 59,097 RSUs convert into common stock, and disposed of 36,974 shares at $27.57 and $28.17 per share to cover tax withholding obligations.
How many Restricted Stock Units were granted to CSTL CEO Derek Maetzold and when do they vest?
Maetzold was granted 102,597 RSUs on March 3, 2026. A footnote states these RSUs vest in four equal annual installments beginning on March 3, 2027, creating a multi-year vesting schedule tied to continued service and potential long-term alignment with shareholders.
What RSU awards previously granted to CSTL’s CEO are referenced in the Form 4 footnotes?
Footnotes reference prior RSU awards of 124,437 units granted March 4, 2024, vesting in four installments from March 4, 2025, and 111,948 units granted March 4, 2025, vesting in four installments from March 4, 2026. These illustrate a recurring annual equity grant pattern.
How does this CSTL Form 4 describe the nature of RSUs reported for Derek Maetzold?
A footnote states each RSU represents the right to receive one share of Castle Biosciences common stock. This means RSUs convert on vesting or exercise into an equivalent number of shares, linking executive compensation directly to the company’s equity performance over time.